Characterization of the solubility of a poorly soluble hydroxylated metabolite in human urine and its implications for potential renal toxicity

Pharmazie

Volumn 60, Issue 5, 2005, Pages 359-363

  Merschman, Sheila A ^a   Rose, M J ^b   Pearce, G E S ^a   Woolf, E J ^a   Schaefer, B H ^a   Huber, A C ^a   Musson, D G ^a   Petty, K J ^a   Rush, D J ^a   Varsolona, R J ^a   Matuszewski, B K ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (5 METHYLISOXAZOL 3 YL) 6 (1 METHYL 1,2,3 TRIAZOL 4 YL)METHYLOXY 1,2,4 TRIAZOLO[3,4 A]PHTHALAZINE; DRUG METABOLITE; NOOTROPIC AGENT; UNCLASSIFIED DRUG;

ADULT; AGED; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CRYSTALLURIA; DRUG HYDROXYLATION; DRUG SAFETY; DRUG SOLUBILITY; DRUG URINE LEVEL; EX VIVO STUDY; FEMALE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CONCENTRATING CAPACITY; MALE; MONKEY; NEPHROTOXICITY; NONHUMAN; NORMAL HUMAN; PRECIPITATION; RAT; TEMPERATURE DEPENDENCE; URINE OSMOLALITY;

ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; HUMANS; HYDROXYLATION; KIDNEY DISEASES; MALE; MASS SPECTROMETRY; PHTHALAZINES; PSYCHOTROPIC DRUGS; RATS; SOLUBILITY; TEMPERATURE; TRIAZOLES;

EID: 21044437030     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Asplin J, DeGanello S, Nakagawa YN, Coe FL (1991) Evidence that nephrocalcin and urine inhibit nucleation of calcium oxalate monohydrate crystals. Am J Physiol 261: F824-F830.
2. Asplin JR, Bushinsky DA, Singharetnam W, Riordon D, Parks JH, Coe FL (1997) Relationship between supersaturation and crystal inhibition in hypercalciuric rats. Kidney Int 51: 640-645.
3. Borghi L, Meschi T, Schianchi T, Briganti A, Guerra A, Allegri F, Novarini A (1999) Urine volume, stone risk factor and preventive measure. Nephron 81: 31-37.
4. Borghi L, Schianchi T, Meschi T, Guerra A, Allegri F, Maggiore U, Novarini A (2002) Comparison of 2 diets for the prevention of recurrent stones in idiopathic hypercalciuria. N Engl J Med 346: 77-84.
5. Cahill DJ, Fry CH, Foxall PJD (2003) Variation in urine composition in the human urinary tract: evidence of urothelial function in situ? J Urol 169: 871-874.
6. Cerini C, Geider S, Dussol B, Hennequin C, Daudon M, Veesler S, Nitsche S, Boistelle R, Berthezene P, Dupuy P, Vazi A, Berland Y, Dagorn JC, Verdier JM (1999) Nucleation of calcium oxalate crystals by albumin: Involvement in the prevention of stone formation. Kidney Int 55: 1776-1786.
7. Chambers MS, Alack JR, Bromidge FA, Broughton HB, Cook S, Dawson GR, Hobbs SC, Maubach KA, Reeve AJ, Seabrook GR, Wafford K, MacLeod AM (2002) 6,7-Dihydro-2-benzothiophen-4(5H)-ones: A novel class of GABA-A alpha-5 receptor inverse agonists. J Med Chem 45: 1176-1179.
8. Coe FL, Nakagawa Y, Parks JH (1991) Inhibitors within the nephron. Am J Kidney Dis 17: 407-413.
9. Curhan GC, Willett WC, Speizer FE, Stampfer MJ (2001) Twenty-four-hour urine chemistries and the risk of kidney stones among women and men. Kidney Int 59: 2290-2298.
10. Hess B, Nakagawa Y, Coe FL (1989) Inhibition of calcium oxalate monohydrate crystal aggregation by urine proteins. Am J Physiol 257: F99-F106.
11. Lipinski CA (2000) Drug-like properties and the causes of poor solubility and poor permeability. J Pharm Tox Meth 44: 235-249.
12. MacLeod AM, Dawson GR, Pillai P, Cook S, Alack JR, Reeve AJ, Jelley RA, Carling R, Streel LJ, McKernan RM, Wafford K, Laughton P, Hill R, Collinson N, Whiling P, Castro JL (2003) Discovery of GABA A alpha-5 subtype selective inverse agonists as cognition enhancers. Abstr Pap - Am Chem Soc 221st: MEDI-187.
13. Martinez F, Mommeja-Marin H, Estepa-Maurice L, Beaufils H, Bochet M, Daudon M, Deray G, Kallama C, Jouanneau C, Le Naour G (1998) Indinavir crystal deposits associated with tubulointerstitial nephropathy. Nephrol Dial Transplant 13: 750-753.
14. Novotny J, Novotny M (2000) Drug nephrotoxicity and its prevention. Biologia 55: 95-102.
15. Rose MJ, Merschman SA, Woolf EJ, Maluszewski BK (1999) Determination of L-756423, a novel HIV protease inhibitor, in human plasma and urine using high-performance liquid chromatography with fluorescence detection. J Chromatogr B 732: 425-435.
16. Rotily M, Leonetti F, Iovanna C, Berthezene P, Dupuy P, Vazi A, Berland Y (2000) Effects of low animal protein or high-fiber diets on urine composition in calcium nephrolithiasis. Kidney Int. 57: 1115-1123.
17. Schwartz M, Kline W, Matuszewski B (1997) Determination of a cyclic hexapeptide (L-743872), a novel pneumocandin antifungal agent in human plasma and urine by high-performance liquid chromatography with fluorescence detection. Anal Chim Acta 352: 299-307.
18. Shah VR Midha KK, Findlay JWA, Hill HM, Hulse JD, McGilveray IJ, McKay G, Miller KJ, Palnaik RN, Powell ML, Tonelli A, Viswanathan CT, Yacobi A (2000) Bioanalytical method validation - a revisit with a decade of progress. Pharm Res 17: 1551-1557.